Voyageur Pharmaceuticals Ltd.

OTC: VYYRF · Healthcare · Drug Manufacturers - Specialty & Generic

Canadian filerHQ Calgary, ABReports USD

#1117 of 1,394 Healthcare companies by revenue

EA Score

——

FH 28DQ —GM —SS 38

v0.1 · 35/100 weight · pillars only

↑ disclosure history, market scale · ↓ operating margin, net margin

Methodology →

Revenue TTM

$22.5k

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$2.5M

Employees

Market cap

$17.1M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$8.3k11.7k CAD2025

Net income-$2.5M-3.5M CAD2025

Operating income-$2.5M-3.5M CAD2025

Total assets$2.2M3.1M CAD2025

Liabilities$1.3M1.9M CAD2025

Equity$894.9k1.3M CAD2025

Revenue trend

FY2018 – FY2025 · USD

FY18

FY19

FY20

FY21

FY22

FY23

FY24

$8.3k

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Voyageur Pharmaceuticals Ltd. booked $8.3k in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -30232.7% net margin.

Peers · Healthcare

Pelthos Therapeutics Inc.35D ProMIS Neurosciences, Inc.——Aytu BioPharma, Inc.53D Werewolf Therapeutics, Inc.——

Key facts

CEOBrent Willis

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersCalgary, AB

ExchangeOTC: VYYRF

Employees6

IPO date2017-10-19

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.